Testing new outcomes in primary Sjögren’s syndrome
Treatments studied
Part of Eyes & vision, Mouth & dental clinical trials.
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign written consent.
- You must have primary Sjögren’s syndrome diagnosed by accepted criteria (ACR/EULAR 2016 or AECG 2002).
- Your symptom level must be high (ESSPRI 5 or more) and your overall body inflammation level must be either lower (ESSDAI < 5) or moderate/high (ESSDAI 5 or more), depending on which group you fit.
- If you can become pregnant, you must have a negative pregnancy test and use highly effective birth control during the study and for 2 years after stopping.
- You must not be in another medicine trial at the same time.
- You must not have certain eye, liver/kidney, infection, blood count, heart rhythm, or cancer conditions that could make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have signs that might mean Sjögren’s syndrome and looks at how well a standardized work-up identifies the condition. It may help doctors confirm the diagnosis earlier and more consistently.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This study tests whether upadacitinib, a pill that reduces inflammation, can help people with Sjögren's syndrome. It aims to see if the drug can lower disease activity and improve symptoms.
This study tests an investigational drug called JH013 for primary Sjögren's syndrome. It aims to reduce dryness and other symptoms like fatigue and joint pain, and may help people with moderate to severe disease activity.
This study tests a low-dose medication called blinatumomab, which targets certain immune cells, to see if it can help control symptoms of moderate to severe Sjögren's syndrome, especially dry eyes. It is for people who have not gotten enough relief from standard treatments.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
Hear when a new Primary Sjögren's Syndrome (pSS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.